Medication info
Flogam Duo Extended-Release Tablets 10/500 mg (Dapagliflozin, Metformin)

Flogam Duo Extended-Release Tablets 10/500 mg (Dapagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
NexPharm Korea Co., Ltd.
Appearance
Pink oval extended-release film-coated tablets
Packaging
28 tablets/box [7 tablets/PTP x 4]
Approval status
Active

MFDS item code 202400167 · Approved 2024.01.23 · Insurance code 662504980

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dosage of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no previous experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no previous experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce the gastrointestinal side effects of metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Since changes may lead to alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patients subsection).

Ingredients

Manufacturer
NexPharm Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control in patients with type 2 diabetes
  • poorly controlled type 2 diabetes
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in combination with dapagliflozin and metformin to assist in blood sugar control for adults with type 2 diabetes. It can effectively manage blood sugar levels as an adjunct to dietary and exercise therapy. Especially for patients with type 2 diabetes whose blood sugar is not adequately controlled, it is important to refer to additional information from professionals regarding the impact of dapagliflozin on the occurrence of cardiovascular events, particularly in those with cardiovascular disease or risk factors. This medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dosage of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no previous experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no previous experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce the gastrointestinal side effects of metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Since changes may lead to alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patients subsection).

Precautions

This medication may rarely cause a serious condition called lactic acidosis, so patients with reduced kidney function or problems with heart, liver, or lung function should be especially cautious. This medication can cause hypoglycemia when used in combination with other diabetes medications, so dosage adjustments may be necessary when used concurrently with insulin or sulfonylureas. Patients with moderate or severe renal impairment, dehydration, serious infections, or cardiovascular issues should not take this medication. If undergoing imaging tests using iodinated contrast agents, this medication should be discontinued 48 hours before the test and resumed only after kidney function is confirmed to be normal. Pregnant or potentially pregnant women and nursing mothers should not use this medication, and its safety and efficacy in children have not been established. This medication can cause depletion of fluid volume and low blood pressure, so elderly patients or those on diuretics or with low blood pressure should be cautious while taking it. There may be an increased risk of genital and urinary tract infections during use, so any related symptoms should be reported to healthcare professionals immediately. Vitamin B12 levels may decrease, so patients taking it long-term should have regular blood tests to monitor this. Excessive alcohol consumption may heighten the risk of side effects with this medication; therefore, it is advisable to avoid alcohol while taking it. Patients scheduled for surgery should discontinue this medication 48 hours before the procedure and can resume it after kidney function has been restored post-surgery. During treatment, dizziness or symptoms of hypoglycemia may occur, requiring caution while driving or operating machinery. Store this medication away from the reach of children and keep it in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • decreased fluid volume
  • thirst
  • diabetic ketoacidosis
Show 86 more
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased kidney creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendonitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • benign prostatic hyperplasia
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pink oval extended-release film-coated tablets

Package unit

28 tablets/box [7 tablets/PTP x 4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.